How are RGEN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RGEN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 54.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$642.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a RGEN strangle?

The breakeven for the RGEN strangle priced on this page is roughly $123.58 and $151.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RGEN market-implied 1-standard-deviation expected move is approximately 15.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current RGEN implied volatility affect this strangle?

RGEN ATM IV is at 54.30% with IV rank near 4.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

RGEN Strangle Strategy

RGEN (Repligen Corporation), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand.

RGEN (Repligen Corporation) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $8.29B, a trailing P/E of 161.19, a beta of 1.08 versus the broader market, a 52-week range of 100.99-175.77, average daily share volume of 1.1M, a public-listing history dating back to 1986, approximately 2K full-time employees. These structural characteristics shape how RGEN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.08 places RGEN roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 161.19 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a strangle on RGEN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current RGEN snapshot

As of June 30, 2026, spot at $136.87, ATM IV 54.30%, IV rank 4.63%, expected move 15.57%. The strangle on RGEN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on RGEN specifically: RGEN IV at 54.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a RGEN strangle, with a market-implied 1-standard-deviation move of approximately 15.57% (roughly $21.31 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RGEN expiries trade a higher absolute premium for lower per-day decay. Position sizing on RGEN should anchor to the underlying notional of $136.87 per share and to the trader's directional view on RGEN stock.

RGEN strangle setup

The RGEN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RGEN near $136.87, the first option leg uses a $145.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RGEN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RGEN shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$145.00	$3.20
Buy 1	Put	$130.00	$3.23

RGEN strangle risk and reward

Net Premium / Debit: -$642.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$642.50
Breakeven(s): $123.58, $151.43
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

RGEN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on RGEN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$12,356.50
$30.27	-77.9%	+$9,330.34
$60.53	-55.8%	+$6,304.18
$90.79	-33.7%	+$3,278.02
$121.06	-11.6%	+$251.86
$151.32	+10.6%	-$10.70
$181.58	+32.7%	+$3,015.46
$211.84	+54.8%	+$6,041.63
$242.10	+76.9%	+$9,067.79
$272.36	+99.0%	+$12,093.95

When traders use strangle on RGEN

Strangles on RGEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RGEN chain.

RGEN thesis for this strangle

The market-implied 1-standard-deviation range for RGEN extends from approximately $115.56 on the downside to $158.18 on the upside. A RGEN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RGEN IV rank near 4.63% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RGEN at 54.30%. As a Healthcare name, RGEN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RGEN-specific events.

RGEN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RGEN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RGEN alongside the broader basket even when RGEN-specific fundamentals are unchanged. Always rebuild the position from current RGEN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on RGEN?: A strangle on RGEN is the strangle strategy applied to RGEN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RGEN stock trading near $136.87, the strikes shown on this page are snapped to the nearest listed RGEN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RGEN strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RGEN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 54.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$642.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RGEN strangle?: The breakeven for the RGEN strangle priced on this page is roughly $123.58 and $151.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RGEN market-implied 1-standard-deviation expected move is approximately 15.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on RGEN?: Strangles on RGEN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RGEN chain.
How does current RGEN implied volatility affect this strangle?: RGEN ATM IV is at 54.30% with IV rank near 4.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.